TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01615302

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mucosa advancement flap
Description: Mucosa advancement flap will be performed at the starting point of the fistula in the rectum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucosa advancement flap
Description: Mucosa advancement flap will be performed at the starting point of the fistula in the rectum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP)
Description: The PRP will be injected into the fistula, after the mucosa advancement flap was created.~For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP.
Study: NCT04897100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Achilles tendon tenotomy
Description: Achilles tendon tenotomy during Ponseti treatment for clubfoot

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Achilles tendon tenotomy
Description: Achilles tendon tenotomy during Ponseti treatment for clubfoot
Study: NCT02444156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indoor rowing
Study: NCT02521454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBRT
Study: NCT04207190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Given PO
Study: NCT04243876

Intervention type: DIAGNOSTIC_TEST
Intervention: paraoxanase enzyme level
Description: presence of paraoxonase enzyme deficiency and associated troponin elevation

Intervention type: DIAGNOSTIC_TEST
Intervention: paraoxanase enzyme level
Description: presence of paraoxonase enzyme deficiency and associated troponin elevation
Study: NCT01416792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Centrifugation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple-pass hemofiltration
Description: The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
Study: NCT01458574

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10 mg orally (PO) twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP690,550
Description: CP-690,550 5 mg orally (PO) twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 10 mg orally (PO) twice a day (BID)
Study: NCT02959489

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alzheimer's Disease Risk Disclosure
Description: Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
Description: Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
Study: NCT03980470

Intervention type: DEVICE
Group type: OTHER
Intervention: TrueFidelity
Description: TrueFidelity (Deep Learning Image Reconstruction, DLIR) software by GE Healthcare.~The medical device in question is a novel reconstruction algorithm for raw CT data which is based on artificial intelligence approaches, namely deep-learning iterative reconstruction (DLIR). This DLIR algorithm will be installed on the console of the CT Revolution scanning device, which is in routine clinical use for cardiac CT scans at the Department of Nuclear Medicine at the University Hospital Zurich. Purpose of this installation is the assessment of the performance of the DLIR algorithm during a limited time span of six weeks.~The algorithm will be CE-marked at the time of installation and use (statement by GE Healthcare provided separately). Its intended use is the reconstruction of CT datasets.~Of note, the novel DLIR algorithm will not substitute any clinical routine procedures currently in use. That is, diagnosis will still be made using the standard reconstruction algorithms.
Study: NCT04197947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro Omega
Description: A neurophysiological navigation system NeuroOmegaTM (Alpha Omega. Israel) was implemented in our group and the operation of this system for aDBS experiment is proved to be successful (Fig 9, 10). This system was proved by both FDA and tFDA. The aDBS stimulation algorithm will be integrated with NeuroOmegaTM. The aDBS stimulation control will achieve through self-developed algorithms or built-in scripting of the system. We introduce NeuroOmega system to conduct the designed aDBS experiment for its multifunction and safety. Our group has established collaboration with Department of Eelectronic Engineering in Chang Gung University (Co-PI HL Chan) and BERTEC in National Ciao Tung University (Co-PI MD Ker). Three postdoctor fellows and one senior engineer have been working on the operation of this aDBS system.~All hardware and software problems could be sorted out in time.
Study: NCT01196975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine GSK2282512A
Description: Single intramuscular dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine GSK2282512A
Description: Single intramuscular dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine GSK2282512A
Description: Single intramuscular dose
Study: NCT02515357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle
Description: Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean lifestyle (food and food group consumption according to the Mediterranean diet, beneficial culinary practices, seasonality and locality of foods consumed, socialization during meals, adequate rest during the day through night sleep and siesta nap, sleep hygiene recommendations and adoption of a physically active lifestyle) and at achieving a 5-10% weight loss.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: General written instructions regarding the adoption of a healthy lifestyle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean dietary pattern (food and food group consumption according to the Mediterranean diet, beneficial culinary practices and seasonality and locality of foods consumed) and at achieving a 5-10% weight loss.
Study: NCT02741297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) System
Description: Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
Study: NCT03703999

Intervention type: DEVICE
Intervention: Type 1 diabetic patients freestyle libre
Description: patients selected to use freestyle libre
Study: NCT01891006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
Study: NCT01196975

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluLavalTM-VB
Description: Single intramuscular dose
Study: NCT02939638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based diet
Description: Weekly instructions will be given to the participants in the intervention group about following vegan diet.
Study: NCT01196975

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluLavalTM-YB
Description: Single intramuscular dose
Study: NCT00747799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib plus Cisplatin and 5-fluorouracil
Description: Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)~* Sorafenib 400 mg bid per daily . Every 21-day cycles.~* Cisplatin 80 mg/m2 day d1, every 21 days cycle.~* 5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles
Study: NCT01365494

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Chick Embryo Cell Inactivated Rabies Vaccine
Description: Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Chick Embryo Cell Inactivated Rabies Vaccine
Description: Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
Study: NCT02960529

Intervention type: PROCEDURE
Intervention: extra-peritoneal high ligation of hernia

Intervention type: PROCEDURE
Intervention: intraabdominal high ligation of hernia
Study: NCT01556113

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omega diet
Description: Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
Study: NCT02939638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: Participants will be asked to continue their usual diets for the 16-week study period.
Study: NCT02506725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prenatal care in groups
Description: We will do prenatal care in groups using centering care pregnancy methodology
Study: NCT03252132

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-week resistance training
Description: Training will consist of a minimum of 5 supervised training sessions every 2 weeks and each session will be approximately 60 minutes in duration. Patients will be performing resistance training consisting of at least 3 exercises affecting the largest muscle groups of the body, training the most basic movement patterns that work the entire body as a coordinated system. Patients will train according to a linear progressive model with a slow increase in weight every training session focusing on the flexors, extensors of the ankle and knee and on flexors, extensors and abductors of the hip.
Study: NCT01803997

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pink and Dude Chef Afterschool Cooking Program
Description: 12 educational cooking classes: two classes per week for six weeks (2 hours each)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pink and Dude Chef Afterschool Cooking Program
Description: 12 educational cooking classes: two classes per week for six weeks (2 hours each)
Study: NCT01605045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-save group
Description: Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique
Description: Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
Study: NCT01503905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2, iv injection, day1, every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2, iv injection, day1, every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: 80mg/ m2, iv injection, day1, every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: 80mg/ m2, iv injection, day1, every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 500 mg/m2, iv injection, day1, every 21 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified radical mastectomy or breast-conserving Surgery
Description: Two weeks after four cycles of neoadjuvant chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified radical mastectomy or breast-conserving Surgery
Description: Two weeks after four cycles of neoadjuvant chemotherapy
Study: NCT01188954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 50 ml/mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Normal Saline/Water
Study: NCT01735877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: During the mirror practices, patients were seated close to a table on which a mirror (35×35cm) was placed vertically. The practice consisted of non paretic-side wrist and finger flexion and extension movements while patients looked into the mirror, watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. Patients could see only the noninvolved hand in the mirror; otherwise, the noninvolved hand was hidden from sight. During the session patients were asked to try to do the same movements with the paretic hand while they were moving the non paretic hand.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The control group performed the same exercises for the same duration but used the nonreflecting side of the mirror in such a way that the paretic hand was hidden from sight. The same therapist delivered the control therapy to the patients. Both the treatment and the control group received limb activation.
Study: NCT00802230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline Infusion
Study: NCT02034929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoCuff-assisted colonoscopy
Description: EC-assisted colonoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy
Description: Standard colonoscopy
Study: NCT01290068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL
Description: Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
Study: NCT03827785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS treatment group
Description: For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 30 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS treatment group
Description: For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday for 30 minutes. Treatment will lasted for 30 days.
Study: NCT01290068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL
Description: Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL
Description: Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal IOL
Description: Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
Study: NCT00395629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox (ICL670)
Study: NCT03841565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT01503905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel (post-operative)
Description: Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
Study: NCT03374150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet counseling
Description: Subjects were given nutrition consultation, diet recipes, and logbook. Counseling was performed once weekly. During 8 weeks of diet program, subjects were instructed to reduce their daily caloric intake by 500 - 1000 kcal from their previous usual daily intake with limitation in low calorie diet range (800-1500 kcal.day) of calorie intake.Follow-up for each subject was performed once daily by person-to-person encounter. Besides, subjects were contacted by everyday cellphone texting and telephone twice a week to control subject's compliance. After 8 weeks of intervention, subjects were invited to revisit the clinic for anthropometry and body composition measurement after completing the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet counseling
Description: Subjects were given nutrition consultation, diet recipes, and logbook. Counseling was performed once weekly. During 8 weeks of diet program, subjects were instructed to reduce their daily caloric intake by 500 - 1000 kcal from their previous usual daily intake with limitation in low calorie diet range (800-1500 kcal.day) of calorie intake.Follow-up for each subject was performed once daily by person-to-person encounter. Besides, subjects were contacted by everyday cellphone texting and telephone twice a week to control subject's compliance. After 8 weeks of intervention, subjects were invited to revisit the clinic for anthropometry and body composition measurement after completing the program.
Study: NCT01503905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel (post-operative)
Description: Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin (post-operative)
Description: Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin (post-operative)
Description: Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (post-operative)
Description: Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
Study: NCT02112812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eradication therapy for H.pylori infection
Description: Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eradication of Helcobacter Pylori
Description: Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
Study: NCT01503905

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin （post-operative)
Description: Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
Study: NCT02112812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eradication therapy for Helicobacter pylori
Study: NCT01869712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cupping therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cupping therapy
Study: NCT01503905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin （post-operative)
Description: Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen (post-operative)
Description: After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen (post-operative)
Description: After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
Study: NCT01869712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Study: NCT02313012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90003
Description: CC-90003 PO once daily
Study: NCT02458105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance & Commitment Therapy
Description: A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention
Description: Supportive conversation at a frequency and length corresponding to the experimental condition.
Study: NCT01617629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1 Dendritic Cell Vaccine (Cvac)
Description: The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks).
Study: NCT00194922

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: E. Coli Strain M17 Probiotic
Description: 30 ml PO BID for 12 weeks
Study: NCT02228213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MIS416
Description: Intravenous administration weekly for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous administration weekly for 52 weeks